Clinical Trial Update: QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating QL1706 in combination with lenvatinib and GEMOX as first-line therapy for unresectable biliary tract tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• LENVIMA (lenvatinib)
• QL1706

Snippet

Sponsor: Eastern Hepatobiliary Surgery Hospital | Conditions: Biliary Tract Tumors | Phase 2 | Status: RECRUITING